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INTRODUCTION: Malignant melanoma is the most aggressive form of skin cancers. Although, 
only 3-5 percent of the skin cancer is melanoma, it possesses the worst prognosis. Nowadays 
one of the most efficient methods in tumor diagnostics is PET imaging; several recent studies 
focus on the development of melanoma specific tracer. Previous researches have shown that 
benzamide derivatives were proven to be specific markers for detection of melanoma. The aim 
of this study was to radiolabel the NODAGA and HBED-CC chelator conjugated PCA derivative 
with Ga-68, and in order to PET imaging, to apply the labeled compounds on animal models of 
melanoma. Moreover, we aimed an extensive testing of the compounds under in vitro and in 
vivo conditions.  
METHODS: The procainamide was conjugated with NODAGA and HBED-CC chelators. The 
complete ligands were purified with RP-HPLC and then were lyophilized. The product was 
characterized by ESI-MS and 1H-NMR. The 68Ge/68Ga generator (Eckert-Ziegler, Obninsk) was 
eluted by using 0.1 M with 5 mL HCl. The labeling was accomplished on pH=4.5-4.6 in NaOAc 
buffer at room temperature and at 95°C for five minutes. The melanin specificity of 68Ga-HBED-
CC-PCA and 68Ga-NODAGA-PCA was investigated in vitro and in vivo using amelanotic (MELUR 
and A375) and melanin containing (B16-F10) melanoma cell lines. Tumour-bearing animals 
were prepared by subcutaneous injection of B16-F10, MELUR and A375 melanoma cells into 
C57BL/6 (n=10) and SCID (n=9) mice. 
RESULTS: Procainamide derivatives conjugated with two different chelators were prepared 
successfully. The compounds possessed excellent radiochemical purity (≥ 98%). The octanol-PBS 
partition coefficients (LogP) of the two radiolabeled compounds were determined. Based on 
the results of the in vitro measurements the 68Ga-NODAGA-PCA showed significantly (p0.01) 
higher accumulation than the 68Ga-HBED-CC-PCA on the B16-F10 cell line.  
CONCLUSION: Two 68Ga labelled PCA derivatives were developed, which could selectively 
accumulate in melanin producing melanoma cells. The uptake values of the compounds are 
diverse and the in vivo preclinical measurements have confirmed, that the 68Ga-NODAGA-PCA 
possessed higher uptake on tumour models. Therefore, it was proven that the 
heterobifunctional chelators also served as pharmacokinetic modifiers, and by their selection 
the distribution profile of the radioligands within the organism can be considerably modifiable. 
